Rory Collins

Sir Rory Collins
Born
Rory Edwards Collins

(1955-01-03) 3 January 1955 (age 68)
Alma mater
Known forUK Biobank
Awards
Scientific career
Fields
InstitutionsUniversity of Oxford
Websitewww.ndph.ox.ac.uk/team/rory-collins

Sir Rory Edwards Collins FMedSci FRS (born 3 January 1955) is a British physician who is Professor of Medicine and Epidemiology at the Clinical Trial Service Unit within the University of Oxford, the head of the Nuffield Department of Population Health and a Fellow of Green Templeton College, Oxford. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies ("meta-analyses"). Since September 2005, he has been the Principal Investigator and Chief Executive of the UK Biobank, a prospective study of 500,000 British people aged 40–69 at recruitment.

Education

Collins was educated at Dulwich College and studied Medicine at St Thomas's Hospital Medical School, part of the University of London (1974-1980), and Statistics at George Washington University from 1976 to 1977 and the University of Oxford from 1982 to 1983.[citation needed]

Career and research

Since 1985, Collins has been co-director with Sir Richard Peto of the University of Oxford's Clinical Trial Services and Epidemiological Studies units. In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation. Since September 2005, he has also been acting as the Principal Investigator and Chief Executive of the UK Biobank, a prospective study of 500,000 British people, aged 40–69 at recruitment.

Collins' work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer.

He has created and led large studies that transformed statins from esoteric drugs for familial hypercholesterolaemia into widely-used generics that prevent millions of heart attacks and ischaemic strokes annually. His large placebo-controlled trials and worldwide Cholesterol Treatment Trialists' meta-analyses confirmed that statins reduce the risk of heart attack, discovered that they reduce the risk of stroke, and demonstrated their safety and efficacy in many different types of patient. His research has been funded by the Medical Research Council (MRC).

Awards and honours

Collins was knighted in the 2011 New Year Honours for services to science. He was elected as a Fellow of the Academy of Medical Sciences in 2004 and a Fellow of the Royal Society (FRS) in 2015.



This page was last updated at 2023-11-30 12:01 UTC. Update now. View original page.

All our content comes from Wikipedia and under the Creative Commons Attribution-ShareAlike License.


Top

If mathematical, chemical, physical and other formulas are not displayed correctly on this page, please useFirefox or Safari